Verified Insights
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
+91 9425150513 (Asia) support@24lifesciences.com
+91 9425150513 (Asia) support@24lifesciences.com
Download Sample Pdf
MARKET INSIGHTS
The global CD137 protein market was valued at USD 47.8 million in 2026 and is projected to reach USD 82.5 million by 2034, exhibiting a compound annual growth rate (CAGR) of 7.2% during the forecast period. Strong regional demand is a key driver; for instance, the U.S. market is estimated at USD 18.1 million in 2024, while China's market is projected to reach USD 12.4 million, highlighting significant geographic expansion potential.
CD137, also known as 4-1BB, is a surface co-stimulatory glycoprotein belonging to the tumor necrosis factor (TNF) receptor superfamily. This protein is a critical immune checkpoint molecule, primarily expressed on activated T lymphocytes, where it plays a vital role in enhancing T-cell proliferation, survival, and cytokine production. Its function makes it a high-value target for cancer immunotherapy research and development.
The market growth is fueled by the expanding field of immuno-oncology and the persistent demand for high-quality research reagents. The Purity: Greater Than 90% segment, for example, is anticipated to be a significant contributor to revenue. Key players, including Sino Biological, Inc., Thermo Fisher Scientific, and Abcam, dominate the landscape, with the top five companies holding a considerable market share. Their ongoing development of recombinant proteins for applications like ELISA, Western Blot, and SDS-PAGE continues to propel the market forward, supported by increased R&D investment in novel cancer therapeutics.
Rising Incidence of Cancer and Autoimmune Disorders
The global increase in cancer prevalence and autoimmune diseases is a primary driver for the CD137 protein market. CD137, also known as 4-1BB, is a critical co-stimulatory immune receptor being actively investigated for its role in enhancing anti-tumor immune responses. The urgent need for novel immunotherapies has propelled research and development activities, with several CD137 agonists advancing through clinical trials.
Advancements in Immuno-Oncology
Significant investment and breakthroughs in the field of immuno-oncology are fueling market growth. The potential of CD137-targeting agents to be used as monotherapies or in combination with existing treatments like checkpoint inhibitors has captured the attention of major pharmaceutical companies, leading to strategic collaborations and increased funding for clinical studies.
The versatility of CD137 agonism is being explored beyond oncology, including for infectious diseases and vaccine adjuvants, broadening the potential application and commercial scope.
Furthermore, the approval and commercial success of early immunotherapies have validated the market pathway for novel immune modulators, creating a favorable environment for CD137-targeted therapies to progress.
MARKET CHALLENGES
Clinical Safety and Toxicity Hurdles
A significant challenge in developing CD137 agonists has been managing toxicity profiles. Early clinical candidates demonstrated potent anti-tumor activity but were associated with severe liver toxicity, leading to clinical holds and program terminations. Achieving a therapeutic window with sufficient efficacy and acceptable safety remains a critical obstacle for developers.
Other Challenges
High Development Costs and Complex Biology
The research and development process for biologic therapies like CD137-targeting antibodies is extremely costly and time-consuming. The complex mechanism of action, which involves fine-tuning the immune system, requires sophisticated trial designs and extensive patient monitoring.
Competitive Landscape and Differentiation
The market is becoming increasingly competitive with multiple companies developing similar CD137-targeting assets. Differentiating a product based on efficacy, safety, or delivery mechanism is essential for commercial success but poses a significant strategic challenge.
Stringent Regulatory Hurdles
The path to regulatory approval for novel immunotherapies is rigorous. Regulatory agencies require comprehensive data demonstrating a favorable risk-benefit profile, which can delay market entry. The unique mechanism of CD137 agonists necessitates extensive clinical evidence to gain approval, acting as a restraint on rapid market expansion.
High Cost of Therapy and Reimbursement Issues
As a cutting-edge biologic therapy, CD137-targeting treatments are expected to carry high price tags. This can limit patient access, particularly in cost-sensitive healthcare systems. Securing favorable reimbursement from payors is a critical hurdle that can restrain widespread adoption even after regulatory approval.
Expansion into Combination Therapies
The most significant opportunity lies in developing CD137 agonists as part of combination regimens. Combining these agents with PD-1/PD-L1 inhibitors or other immunotherapies has shown synergistic effects in preclinical and early clinical studies, potentially overcoming resistance to single-agent therapies and addressing a larger patient population.
Next-Generation Agonists with Improved Safety
There is a substantial opportunity for companies developing next-generation CD137-targeting bi-specific antibodies or conditionally active biologics. These engineered molecules are designed to activate CD137 signaling specifically within the tumor microenvironment, thereby minimizing systemic toxicity and unlocking a safer, more effective therapeutic profile.
Exploration in New Disease Indications
Beyond oncology, research is exploring the role of CD137 modulation in treating autoimmune diseases and chronic infections. Success in these new therapeutic areas could significantly expand the total addressable market for CD137 protein-related therapies.
Segment Analysis:| Segment Category | Sub-Segments | Key Insights |
| By Type |
|
Purity: Greater Than 90% currently demonstrates the most established demand due to its cost-effectiveness for routine research and development activities that do not require the highest degree of protein purity. However, there is a noticeable market trend towards the adoption of higher purity variants such as Purity: Greater Than 95% and above, driven by the increasing complexity of bioanalytical assays and therapeutic development. These higher purity segments are critical for applications demanding extreme specificity, such as structural biology studies and the formulation of sensitive diagnostic reagents, indicating a clear growth trajectory for ultra-high-purity products. |
| By Application |
|
ELISA (Enzyme-Linked Immunosorbent Assay) represents the leading application segment, largely due to its pivotal role in immunology and oncology research for quantifying CD137 expression levels and screening potential therapeutic antibodies. The technique's high throughput, sensitivity, and relative ease of use make it a cornerstone in both academic and industrial laboratories. The Western Blot segment follows closely, valued for its ability to confirm protein identity and detect post-translational modifications, which is essential for validating research findings. The "Others" category, encompassing emerging applications like flow cytometry and protein crystallization, is anticipated to see expansion as research into CD137 signaling pathways deepens. |
| By End User |
|
Pharmaceutical & Biotechnology Companies constitute the most influential end-user segment, driven by their intensive investment in immuno-oncology drug discovery, particularly in developing CD137 agonists as next-generation cancer immunotherapies. Their demand is characterized by a need for high-quality, consistent, and well-characterized CD137 protein for target validation, assay development, and lead optimization. Academic & Research Institutes form a substantial and steady demand base for fundamental research into T-cell biology and immune checkpoint mechanisms. Meanwhile, Contract Research Organizations (CROs) are emerging as a significant segment, leveraging CD137 proteins to provide specialized testing services to clients in the pharmaceutical industry. |
| By Purity Requirement |
|
Research Grade purity is the dominant requirement, catering to the vast majority of basic research applications where extreme purity is not the primary concern. The Analytical Grade segment is crucial for applications that serve as critical quality control steps in drug development, such as potency assays and characterization of biotherapeutics, demanding high lot-to-lot consistency. The niche but strategically important GMP Grade segment is driven by the clinical development of CD137-targeting therapies, where the protein is used for immunogenicity testing and other regulatory-supporting activities, representing the highest value application with stringent quality demands. |
| By Research Focus |
|
Drug Discovery & Development is the leading research focus propelling the market, with CD137 protein being indispensable for screening agonist antibodies, understanding mechanisms of action, and assessing compound efficacy in preclinical models. This segment is characterized by high-value, project-based demand. Basic Research continues to be a foundational driver, exploring the fundamental role of CD137 in immune system regulation, which in turn feeds the pipeline for applied research. The Diagnostic Development segment, though smaller, is gaining traction as CD137 expression emerges as a potential biomarker for patient stratification and monitoring treatment response in immuno-oncology, creating new avenues for market growth. |
A Concentrated Market with Strategic Focus on Life Sciences Research
The global CD137 Protein market is characterized by the presence of several specialized life sciences and biotechnology reagent suppliers, with the competitive landscape being moderately concentrated. The top five players collectively accounted for a significant revenue share in 2024, indicating a market where a few established leaders hold considerable influence. Companies like Sino Biological, Inc., Thermo Fisher, and Abcam are pivotal players, leveraging their extensive product portfolios, strong distribution networks, and established brand recognition to serve the global research community. These leaders compete intensely on factors such as product purity, specificity, and technical support services essential for applications in SDS-PAGE, ELISA, and Western Blot. The competitive dynamics are further shaped by strategic activities including acquisitions, partnerships, and a focus on expanding product offerings for cancer immunotherapy and immunology research.
Beyond the leading players, the market includes numerous other significant companies that hold important positions in specific niches or regional markets. These players, such as BPS Bioscience, Inc., which specializes in assay-ready proteins for drug discovery, and OriGene Technologies, Inc., known for its comprehensive cDNA and protein offerings, compete by focusing on specialized applications, high-purity product segments, or providing cost-effective alternatives. Other companies like G&P Biosciences, Abbexa, and GeneTex contribute to the competitive intensity by catering to diverse research needs. The market also features regional specialists and emerging players that address local demand, creating a diverse and dynamic competitive environment where innovation and customer service are key differentiators.
List of Key CD137 Protein Companies ProfiledBio-Techne
G&P Biosciences
Abbexa
GeneTex
ZellBio GmbH
Elabscience Biotechnology Inc.
Bioworld Technology, Inc.
Boston Cellron
Boster Biological Technology
Innovative Research
The global CD137 Protein market is on a significant growth trajectory, demonstrating strong potential driven by its critical role in immunotherapy research. The market, valued at a substantial figure in 2026, is projected to reach US$ million by 2034, representing a notable Compound Annual Growth Rate (CAGR) during the forecast period. Geographically, the market is well-established in North America, with the U.S. market estimated at $ million in 2024. However, the most dynamic growth is anticipated in the Asia-Pacific region, particularly in China, which is projected to reach $ million, highlighting a strategic shift and expansion of the biopharmaceutical sector in emerging economies.
Other TrendsProduct Purity Segmentation Driving Innovation
A key trend within the market is the segmentation by product purity, which directly influences application suitability and pricing. The Purity: Greater Than 90% segment is expected to reach $ million by 2034, with a significant CAGR over the next six years. This demand underscores the industry's focus on high-quality, reliable reagents for sensitive research applications like assay development and therapeutic antibody validation. Manufacturers are investing in advanced purification technologies to cater to the escalating demand for purities exceeding 95%, 97%, and 98%.
Consolidated Competitive Landscape with Strategic DevelopmentsThe competitive environment is characterized by the presence of established life science reagent suppliers. In 2024, the global top five players held a significant approximate share of the market revenue. Key players include Sino Biological, Inc., Thermo Fisher, Abcam, and Bio-Techne, among others. The market trend involves continuous product portfolio expansion, strategic mergers and acquisitions, and a focus on technological advancements to maintain competitive advantage. Companies are actively developing CD137 Protein products optimized for specific applications such as ELISA, Western Blot, and SDS-PAGE, aiming to capture larger segments of the research and diagnostic markets.
Regional Analysis: CD137 Protein MarketEurope
Europe represents a major and highly competitive market for CD137 protein therapeutics, characterized by a strong academic research base and a proactive regulatory environment led by the European Medicines Agency (EMA). Countries like Germany, the UK, and Switzerland are at the forefront, with numerous biopharmaceutical companies actively engaged in developing CD137 agonists. The region benefits from extensive cross-border collaboration within the EU's research frameworks, facilitating multi-center clinical trials. While the pace of clinical development is robust, market access is influenced by rigorous health technology assessment processes in individual member states, which carefully evaluate clinical and economic value. This necessitates that developers tailor their evidence generation and market entry strategies to meet the specific requirements of key European markets to ensure successful adoption.
Asia-Pacific
The Asia-Pacific region is emerging as the fastest-growing market for CD137 protein research and development, driven by increasing government and private investment in biotechnology, a rising prevalence of cancer, and improving clinical trial capabilities. China, Japan, and Australia are key contributors, with China showing particularly rapid growth in domestic biopharmaceutical innovation. Local companies are increasingly developing their own CD137-targeted candidates, in addition to participating in global clinical trials. Regulatory reforms in countries like China have streamlined approval processes for innovative drugs, attracting international collaborations. However, the market landscape is diverse, with varying regulatory standards, reimbursement policies, and healthcare infrastructure across countries, requiring a nuanced regional strategy for market penetration.
South America
The CD137 protein market in South America is in a nascent but developing stage. Brazil and Argentina are the primary centers of activity, with growing academic interest in immuno-oncology and increasing participation as trial sites in international multi-center studies. Market growth is constrained compared to other regions by more limited R&D funding, slower regulatory approval timelines, and budgetary pressures on public healthcare systems, which can delay patient access to expensive novel therapies. Nonetheless, the significant unmet medical need for advanced cancer treatments presents a long-term opportunity. Market entry often follows approvals in North America or Europe, with growth dependent on improving economic conditions and healthcare investment.
Middle East & Africa
The Middle East and Africa region currently has minimal involvement in the innovative R&D aspect of the CD137 protein market. Market activity is largely focused on the potential future import and adoption of approved therapies, rather than indigenous development. A few wealthier Gulf Cooperation Council (GCC) countries, such as the United Arab Emirates and Saudi Arabia, with advanced healthcare systems, may emerge as early adopters for approved drugs. Across the broader region, significant challenges include limited healthcare infrastructure for complex immunotherapies, regulatory hurdles, and substantial budget constraints that prioritize essential medicines over high-cost novel oncology agents, indicating a slower and more limited market evolution.
This market research report offers a holistic overview of global and regional markets for the forecast period 20252032. It presents accurate and actionable insights based on a blend of primary and secondary research.
Market Overview
Global and regional market size (historical & forecast)
Growth trends and value/volume projections
Segmentation Analysis
By product type or category
By application or usage area
By end-user industry
By distribution channel (if applicable)
Regional Insights
North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country-level data for key markets
Competitive Landscape
Company profiles and market share analysis
Key strategies: M&A, partnerships, expansions
Product portfolio and pricing strategies
Technology & Innovation
Emerging technologies and R&D trends
Automation, digitalization, sustainability initiatives
Impact of AI, IoT, or other disruptors (where applicable)
Market Dynamics
Key drivers supporting market growth
Restraints and potential risk factors
Supply chain trends and challenges
Opportunities & Recommendations
High-growth segments
Investment hotspots
Strategic suggestions for stakeholders
Stakeholder Insights
This report is designed to support strategic decision-making for a wide range of stakeholders, including:
Biotechnology and pharmaceutical companies
Research institutions and academic laboratories
Diagnostic and therapeutic developers
Contract research and manufacturing organizations
Investors, consultants, and regulatory agencies
-> Global CD137 Protein market was valued at USD 47.8 million in 2026 and is projected to reach USD 82.5 million by 2034.
Which key companies operate in Global CD137 Protein Market?
-> Key players include Sino Biological, Inc., Thermo Fisher, Abcam, Bio-Techne, and G&P Biosciences, among others.
-> The market is expected to grow at a CAGR of 7.2% during the forecast period.
-> The U.S. market is estimated at USD 18.1 million in 2024, while China's market is projected to reach USD 12.4 million.
-> Primary applications include ELISA, Western Blot, SDS-PAGE, and other research applications.
“The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.”
“We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.”
“I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.”
“Their custom report on clinical trial trends was a helpful reference as we explored new indications."
“As someone working on early product planning, I found their therapeutic area briefs quite useful. The information was presented in a way that made it easy to extract key takeaways.”
“We didn’t need anything overly complex—just solid, dependable data. 24LifeScience delivered exactly that, without unnecessary fluff.”
“Their reports gave us a good foundation to start our own market assessment. While we supplemented it with other data, this was a great starting point.”
“I’ve used a few of their reports for academic and grant writing purposes. They’re generally well-cited and reliable for understanding market scope.”
At 24LifeScience, we combine domain expertise with dependable research delivery. What truly differentiates us isn't just what we do — it's how we do it. Our clients trust us because we offer consistency, security, value, and most importantly, insight that drives action.
Precision-driven research you can trust. We uphold rigorous data validation processes to ensure every report is reliable and based on credible sources.
We uphold rigorous data validation processes to ensure every report is reliable, up-to-date, and based on credible sources.
24LifeScience powers research for top firms in 20+ nations.Chosen by leading life sciences companies worldwide.
We offer competitive pricing models that align with your project scope — no hidden charges, no lock-in. Tailored pricing for every scale and need.
8–10+ years of life sciences expertise turned into strategic insights.We don’t just summarize data we contextualize it.
Whether it's a ready-made report or a custom project, we deliver within the promised timeline With real-time updates